Fibroblast growth factor 21
FGF21proteinFGF21 is a stress-responsive metabolic hormone linked to atherosclerosis and MI risk through systemic glucose and lipid homeostasis rather than direct plaque-destabilization mechanisms.
Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencemedium
RationaleSystemic metabolic regulator; associates with atherosclerosis progression but acts off the atherothrombotic cascade.
Also acts inVascular inflammation
Druggability
Not assessed (no mapped human gene target).
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I32
C — confounder / Type-II68
A — assay feasibility68
E — evidence strength25
T1DI (composite)5
Specificity differential (R−C)-35.7
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(1)
- Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine.International journal of biological sciences · 2023 · PMID 36594101 · doi